Nonsteroidal Anti-Inflammatory Drugs, Alone or Combined With Opioids, for Cancer Pain Brief description of the intervention, explicit identification of the primary end point, and presentation of ...
MILWAUKEE, Oct. 30, 2025 /PRNewswire/ -- The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2025, more than 1,300, including many clinical based ...
Real-world data from 844,000 patient records highlight the power of remote therapeutic monitoring to improve outcomes and reduce risk in chronic pain care The abstract presents a retrospective cohort ...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 28, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, ...
Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting Oral presentation on SAR’579 / IPH6101, a potential first-in-class NKp46/CD16-based NK cell engager targeting CD123; ...
Researchers in the Ivy Center's pharmacokinetics lab analyze tumor tissue to measure drug concentrations, helping to assess how effectively drugs penetrate tumors and reach their intended targets.
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (ALXO),, an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today ...
PENNINGTON, N.J. and SAN DIEGO, May 21, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (the "Company" or "OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer ...
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are ...
To examine publication outcomes of neonatology abstracts presented at Pediatric Academic Society (PAS) meeting, and to analyze variables affecting publication. All neonatology studies accepted for ...
MARSEILLE, France--(BUSINESS WIRE)-- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today three abstracts including Innate’s product candidates have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback